Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer

Future Oncology
Amir Mehrvarz SarshekehScott Kopetz

Abstract

Nivolumab is a PD-1 inhibitor approved for the use in treatment of multiple tumor types (such as melanoma, non-small-cell lung cancer, renal cell carcinoma, urothelial cancer and Hodgkin's lymphoma). In July 2017, the US FDA granted accelerated approval of this agent for the treatment of metastatic colorectal cancer patients whose tumor harbors deficient mismatch repair, or microsatellite-instability high and have progressed on conventional chemotherapy. In this review, we will discuss the use, efficacy, and safety of this agent in microsatellite-instability high metastatic colorectal cancer.

References

May 7, 1993·Science·S N ThibodeauD Schaid
May 30, 2006·Advances in Immunology·Charles G DrakeDrew M Pardoll
Jan 5, 2008·Annual Review of Immunology·Mary E KeirArlene H Sharpe
Oct 3, 2008·The American Journal of Surgical Pathology·Joel K GreensonStephen B Gruber
Nov 8, 2008·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Jenny N PoynterUNKNOWN Colon Cancer Family Registry Investigators
Nov 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Federica Di NicolantonioAlberto Bardelli
Jan 24, 2009·British Journal of Cancer·M KoopmanJ H J M van Krieken
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Albert de la Chapelle, Heather Hampel
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian
Nov 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L TopalianDrew M Pardoll
Dec 24, 2011·Nature·Ira MellmanGlenn Dranoff
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Nov 22, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Evan J LipsonSuzanne L Topalian
Jan 10, 2014·Cancer Medicine·David F McDermott, Michael B Atkins
Aug 21, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sabine VenderboschMiriam Koopman
Jun 2, 2015·The New England Journal of Medicine·Dung T LeLuis A Diaz
May 7, 2016·BMC Medicine·Sofia FarkonaIvan M Blasutig
Jan 23, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael J OvermanThierry André

❮ Previous
Next ❯

Citations

Feb 5, 2019·Molecular Oncology·Nicole M ReillyAlberto Bardelli
Aug 25, 2020·Annals of Laboratory Medicine·Yiming ZhongMarilyn M Li
Jun 18, 2020·Frontiers in Immunology·Yu-Chen ChuangTsung-Hsien Chuang
Apr 8, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Van K Morris, Tanios Bekaii-Saab
Jan 9, 2021·Journal of Immunotherapy·Carolina Mendonça GorgulhoMichael T Lotze
Sep 21, 2020·Archives of Medical Research·Carlos Torres-CabalaWen-Jen Hwu

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
biopsy

Clinical Trials Mentioned

NCT02460198
NCT02060188
NCT03026140
NCT02948348
NCT03085914
NCT02327078
NCT02423954
NCT02335918
NCT02636036
NCT03104439

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.